Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0363220220600080483
Korean Journal of Dermatology
2022 Volume.60 No. 8 p.483 ~ p.490
Adverse Events and Safety of Oral Cyclosporine for Dermatoses among Children and Adolescents: A Single Center Study
Kim Yul-Hee

Han Hee-Jeong
Kang Hee-Young
Park Young-Joon
Choi Jee-Woong
Abstract
Background: Cyclosporine (CS) is widely used in various dermatological diseases, and its range of usage has beenexpanded to younger patients. However, data on the safety of CS in children and adolescents are limited.

Objective: This study aimed to investigate the adverse events and safety of CS in pediatric and adolescent patientswith dermatologic diseases.

Methods: This retrospective study included 992 pediatric patients (¡Ã12 and £¼19 years of age) having administeredoral CS for dermatological reasons between 2010 and 2021.

Results: Among the 992 patients, 57 (5.7%) reported adverse events at the clinic. Gastrointestinal symptoms werethe most common adverse events (2.6%). Other adverse events included hypertrichosis (1.4%) and headaches (0.6%).
During subgroup analysis, hypertrichosis was found more frequently in pediatric patients (age £¼12 years), and thecumulative dose of CS was higher (¡Ã420 mg/kg). Of the 150 patients who underwent laboratory tests, 28 (18.7%)showed abnormal results, including an increase in serum creatinine (8.0%), hypercholesterolemia (6.7%), and urea(2.7%).

Conclusion: The use of CS in pediatric dermatoses resulted in a low frequency of adverse events, and all thepatients showed reversible courses without serious complications. The study suggest that dermatologists should safelyadminister oral CS with detailed history taking and periodic laboratory tests.
KEYWORD
Adolescent, Adverse effects, Cyclosporine, Safety
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø